Vimarsana
Biggest News Aggregation in the World

Page 33 - Expanded Access Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Expanded Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Expanded Access Program Today - Breaking & Trending Today

RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results - Vimarsana News

RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results

Published: March 17, 2022

/PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its operational...

Source: prnewswire.com
Related Topics:
United Arab EmiratesUnited StatesSouth KoreaUnited KingdomSouth AfricaSaudi ArabiaSouth KoreanAmber FennellDror Ben AsherRedhill BiopharmaBryan GibbsAdi FrishMicha Ben ChorinKukbo CoCalifornia Medicaid Health CareGhassan Aboud GroupRedhill Biopharma LtdNational Medicare PartDevelopment ExpensesCompany Annual Report On FormExchange CommissionCompany Expanded Access ProgramKorea Kukbo CoGaelan Medical TradeGulf Cooperation Council Region Saudi Arabia
MaaT Pharma to Present Promising Clinical Data for Lead Therapeutic Candidate MaaT013 at 48th EBMT Annual Meeting - Vimarsana News

MaaT Pharma to Present Promising Clinical Data for Lead Therapeutic Candidate MaaT013 at 48th EBMT Annual Meeting

Published: March 17, 2022

Data from 76 patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013 will be presented. Oral presentation will highlight MaaT013's potential in improving survival outcome for

Source: finanznachrichten.de
Related Topics:
United StatesMicrobiotherapy MaaFlorent MalardDrug AdministrationEarly Access ProgramTrophic CommunicationsMeeting Of The European Society For BloodAmerican Society Of HematologySorbonne UniversityEuropean Medicines AgencyAccess ProgramGraft Vs Host DiseaseGraft Versus Host DiseaseAmerican SocietyAnnual MeetingEuropean SocietyMarrow TransplantationAssociate ProfessorSaint Antoine HospitalHeracles StudyExpanded Access ProgramMicrobiome EcosystemOrphan Drug DesignationMaat PharmaMicrobiome Ecosystem Therapies
RedHill Biopharma Announces Record Quarterly Revenues and First Commercial Operations Breakeven - Vimarsana News

RedHill Biopharma Announces Record Quarterly Revenues and First Commercial Operations Breakeven

Published: February 17, 2022

/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today provided a business update for...

Source: prnewswire.com
Related Topics:
Amber FennellDror Ben AsherRedhill BiopharmaAdi FrishInternational Financial Reporting StandardsRedhill Biopharma LtdExchange CommissionCompany Annual Report On FormCompany Expanded Access ProgramPricewaterhousecoopers InternationalBusiness DevelopmentInternational Accounting Standards BoardChief Executive OfficerHill BiopharmaPrivate Securities Litigation Reform ActInternational Accounting StandardsExpanded Access ProgramAnnual ReportBusiness Development OfficerUnited KingdomCertified Public AccountantsPricewaterhousecoopers International LimitedRedhill Biopharma Ltd
RedHill Biopharma Announces Record Quarterly Revenues and First Commercial Operations Breakeven - Vimarsana News

RedHill Biopharma Announces Record Quarterly Revenues and First Commercial Operations Breakeven

Published: February 17, 2022

TEL AVIV, Israel and RALEIGH, N.C., Feb. 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. , a specialty biopharmaceutical company, today provided a business update for the fourth quarter of... | February 17, 2022

Source: marketscreener.com
Related Topics:
Amber FennellDror Ben AsherRedhill BiopharmaAdi FrishInternational Financial Reporting StandardsRedhill Biopharma LtdExchange CommissionCompany Annual Report On FormCompany Expanded Access ProgramPricewaterhousecoopers InternationalBusiness DevelopmentInternational Accounting Standards BoardChief Executive OfficerHill BiopharmaPrivate Securities Litigation Reform ActInternational Accounting StandardsExpanded Access ProgramAnnual ReportBusiness Development OfficerUnited KingdomCertified Public AccountantsPricewaterhousecoopers International LimitedRedhill Biopharma Ltd Stock ExchangePress ReleaseUarter Rdhl Us7574681034
U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer - Vimarsana News

U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer

Published: February 15, 2022

/PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced that the U.S. Food and Drug Administration...

Source: prnewswire.com
Related Topics:
Priyanka ShahCharles BaumTemre JohnsonPrnewswire Mirati Therapeutics IncThoracic Oncology At Dana Farber Cancer InstituteDrug AdministrationMirati Therapeutics IncExchange CommissionLowe CenterAccess ProgramNew Drug ApplicationPrescription Drug User Fee ActionAccelerated ApprovalTime Oncology ReviewBreakthrough Therapy DesignationThoracic OncologyDana Farber Cancer InstituteMirati TherapeuticsExpanded Access Program